On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...

Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one ...

The science event aims to test the chemistry knowledge and skills of middle school students through a fun, hands-on ...

RAHWAY, N.J., January 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly ...

Tyrease Hunter led second-seeded Roselle Catholic, No. 1 in the NJ.com Top 20, with 32 points, four rebounds, seven assists and six steals in a 90-65 triumph against 10th-seeded Rahway in the ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, though the drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares. The Rahway, N ...

Shares of Merck slid Tuesday after the drugmaker ... earnings of $9.13 per share on $67.07 billion in sales for the Rahway, New Jersey, company. For the recently completed fourth quarter, Merck ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo, is ...

and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...